Table 1.

Application of nanoparticles in the prevention of MI.

Types of Nanoparticles	Payload	Target	Animal Model	Outcomes	Ref.
PLGA nanoparticles	siCamk2g	Macrophages	LDLR−/−mice	Necrotic core area decreased, fibrous cap thickness increased, and plaque stability increased	[95]
Macrophage membrane-coated PLGA nanoparticles	Rapamycin	AS plaque	ApoE−/−mice	Plaque lipids were reduced and necrotic core area was reduced	[96]
Macrophage membrane-coated nanoparticles	Atorvastatin	ROS	ApoE−/−mice	Plaque area and necrotic core area were significantly reduced	[97]
PLGA nanoparticles	Colchicine	AS plaque	ApoE−/−mice	Plaque lipid deposition was reduced and plaque area was reduced	[98]
Lipid nanoparticles	Apolipoprotein A-I	AS plaque	LDLR−/−mice	Inhibits the inflammatory response of macrophages, inhibits AS, and stabilizes AS plaques	[99]
Erythrocyte membrane-coated stellate polymers	Probucol	ROS	ApoE−/−mice	The formation of foam cells was inhibited and the plaque area was reduced	[100]
Mannose-modified dendritic nanoparticles	SR-A siRNA and LXR ligands	Macrophages	LDLR−/−mice	Plaque area was reduced and aortic cholesterol content was reduced	[101]
Hyaluronic acid-modified liposomes	Rosuvastatin	AS plaque	ApoE−/−mice	The levels of proinflammatory factors and foam cells were reduced, and plaque area was reduced	[102]
Micellar nanoparticles	microRNA-145	Vascular smooth muscle cells	ApoE−/−mice	Plaque size and overall lesion area were reduced	[103]
Macrophage membrane-coated nanoparticles	Methotrexate	AS plaque	ApoE−/−mice	Plaque area and plaque lipid deposition were reduced	[104]